© 2005 Oxford University Press
ARTICLE |
Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains
Affiliations of authors: Centre for Vascular Research, University of New South Wales and Department of Haematology, Prince of Wales Hospital, Sydney, Australia (PJD, ASD, PJH); The Centenary Institute of Cancer Medicine and Cell Biology, Newtown, New South Wales, Australia (KMT, JDA); College of Science, Technology and Environment, University of Western Sydney, Penrith South DC, New South Wales, Australia (VJH); Ramaciotti Centre for Gene Function Analysis, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, Australia (VJH, IWD); Children's Cancer Institute Australia for Medical Research, Randwick (PJH)
Correspondence to: Philip J. Hogg, PhD, Center for Vascular Research, School of Medical Sciences, University of New South Wales, Sydney NSW 2052 Australia (e-mail: p.hogg{at}unsw.edu.au).
Background: The synthetic tripeptide arsenical 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is an angiogenesis inhibitor that targets the mitochondria of actively dividing but not quiescent endothelial cells, arresting their proliferation and causing apoptosis. Normal endothelial cells are much more sensitive to GSAO than tumor cells. To elucidate the mechanism of tumor cell resistance, we identified yeast genes that are necessary for resistance to GSAO. Methods: We screened a genome-wide set of 4546 Saccharomyces cerevisiae deletion strains to identify GSAO-sensitive strains. We then examined GSAO accumulation in and proliferation activity of endothelial cells (BAECs) and tumor cells treated with GSAO and modulators of pathways and proteins identified in the yeast screen. We also examined GSAO effects on proliferation of mammalian cells transfected with transporter protein constructs. Results: Eighty-eight deletion strains were sensitive to GSAO. The most sensitive strains had deletions of genes whose products are involved in vacuolar function (corresponding to drug transport in mammalian cells) and glutathione synthesis. BAECs were more sensitive to GSAO than tumor cells, and cell sensitivity to GSAO was approximately proportional to cellular glutathione levels. Treatment of BAECs and tumor cells with MK-571, an inhibitor of multidrug resistance–associated protein (MRP), or with buthionine sulfoximine, an inhibitor of glutathione synthesis, increased their sensitivity to GSAO. Mammalian cells transfected with MRP1 or MRP2 were resistant to GSAO, whereas cells transfected with MRP3, MRP4, MRP5, P-glypoprotein, or breast cancer resistance protein were not. Conclusions: Differences in MRP activity and cellular glutathione levels contribute to the selectivity of GSAO for endothelial versus tumor cells. MRP1 and/or MRP2 may transport GSAO from resistant cells, with glutathione acting as a cotransporter. Genetic screening in yeast is a powerful tool for understanding drug action in mammalian cells.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Chamilos, R. E. Lewis, G. A. Lamaris, N. D. Albert, and D. P. Kontoyiannis Genomewide Screening for Genes Associated with Gliotoxin Resistance and Sensitivity in Saccharomyces cerevisiae Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1325 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Dilda, S. Decollogne, M. Rossiter-Thornton, and P. J. Hogg Para to Ortho Repositioning of the Arsenical Moiety of the Angiogenesis Inhibitor 4-(N-(S-Glutathionylacetyl)Amino)Phenylarsenoxide Results in a Markedly Increased Cellular Accumulation and Antiproliferative Activity Cancer Res., December 15, 2005; 65(24): 11729 - 11734. [Abstract] [Full Text] [PDF]
|
|